The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease

Makoto Naganuma, Toshimitsu Fujii, Mamoru Watanabe

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Intravenous cyclosporine A (CsA) is an effective treatment for patients with severe, steroid-refractory ulcerative colitis (UC). Like the response to CsA, clinical trials have shown that two-thirds of patients with refractory UC respond to tacrolimus therapy. However, it is unclear how/when this agent should be used for patients with active UC. Methods: We reviewed the results of previous studies regarding calcineurin inhibitors in UC patients. We examined the best way to use tacrolimus to obtain maximum efficacy by comparing the results from clinical trials with those from a recent survey in Japan. Results: Calcineurin inhibitors are useful to induce remission in patients with refractory UC; however, the long-term prognosis has not been shown to be improved by CsA. Early intervention with CsA/tacrolimus may improve the long-term prognosis of UC patients just as infliximab does for Crohn's disease patients. Recent studies have indicated that a fasting state and administration of a higher dosage of tacrolimus at the beginning of therapy are critical in ensuring that the target trough concentration of the agent is reached. Conclusions: The use of higher initial doses of tacrolimus ensured that patients achieved their target levels. Further studies will be needed to elucidate the efficacy of top-down therapy with tacrolimus in patients with UC. Physicians must know how to use calcineurin inhibitors to obtain maximum efficacy.

Original languageEnglish
Pages (from-to)129-137
Number of pages9
JournalJournal of Gastroenterology
Volume46
Issue number2
DOIs
Publication statusPublished - 2011 Feb
Externally publishedYes

Fingerprint

Inflammatory Bowel Diseases
Ulcerative Colitis
Tacrolimus
Cyclosporine
Clinical Trials
Calcineurin Inhibitors
Therapeutics
Crohn Disease
Fasting
Japan
Steroids
Physicians

Keywords

  • Cyclosporine A
  • Infliximab
  • Refractory ulcerative colitis
  • Tacrolimus

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. / Naganuma, Makoto; Fujii, Toshimitsu; Watanabe, Mamoru.

In: Journal of Gastroenterology, Vol. 46, No. 2, 02.2011, p. 129-137.

Research output: Contribution to journalArticle

Naganuma, Makoto ; Fujii, Toshimitsu ; Watanabe, Mamoru. / The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. In: Journal of Gastroenterology. 2011 ; Vol. 46, No. 2. pp. 129-137.
@article{9a4167d7819f4d7a8db30d48aa77cea9,
title = "The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease",
abstract = "Background: Intravenous cyclosporine A (CsA) is an effective treatment for patients with severe, steroid-refractory ulcerative colitis (UC). Like the response to CsA, clinical trials have shown that two-thirds of patients with refractory UC respond to tacrolimus therapy. However, it is unclear how/when this agent should be used for patients with active UC. Methods: We reviewed the results of previous studies regarding calcineurin inhibitors in UC patients. We examined the best way to use tacrolimus to obtain maximum efficacy by comparing the results from clinical trials with those from a recent survey in Japan. Results: Calcineurin inhibitors are useful to induce remission in patients with refractory UC; however, the long-term prognosis has not been shown to be improved by CsA. Early intervention with CsA/tacrolimus may improve the long-term prognosis of UC patients just as infliximab does for Crohn's disease patients. Recent studies have indicated that a fasting state and administration of a higher dosage of tacrolimus at the beginning of therapy are critical in ensuring that the target trough concentration of the agent is reached. Conclusions: The use of higher initial doses of tacrolimus ensured that patients achieved their target levels. Further studies will be needed to elucidate the efficacy of top-down therapy with tacrolimus in patients with UC. Physicians must know how to use calcineurin inhibitors to obtain maximum efficacy.",
keywords = "Cyclosporine A, Infliximab, Refractory ulcerative colitis, Tacrolimus",
author = "Makoto Naganuma and Toshimitsu Fujii and Mamoru Watanabe",
year = "2011",
month = "2",
doi = "10.1007/s00535-010-0352-z",
language = "English",
volume = "46",
pages = "129--137",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease

AU - Naganuma, Makoto

AU - Fujii, Toshimitsu

AU - Watanabe, Mamoru

PY - 2011/2

Y1 - 2011/2

N2 - Background: Intravenous cyclosporine A (CsA) is an effective treatment for patients with severe, steroid-refractory ulcerative colitis (UC). Like the response to CsA, clinical trials have shown that two-thirds of patients with refractory UC respond to tacrolimus therapy. However, it is unclear how/when this agent should be used for patients with active UC. Methods: We reviewed the results of previous studies regarding calcineurin inhibitors in UC patients. We examined the best way to use tacrolimus to obtain maximum efficacy by comparing the results from clinical trials with those from a recent survey in Japan. Results: Calcineurin inhibitors are useful to induce remission in patients with refractory UC; however, the long-term prognosis has not been shown to be improved by CsA. Early intervention with CsA/tacrolimus may improve the long-term prognosis of UC patients just as infliximab does for Crohn's disease patients. Recent studies have indicated that a fasting state and administration of a higher dosage of tacrolimus at the beginning of therapy are critical in ensuring that the target trough concentration of the agent is reached. Conclusions: The use of higher initial doses of tacrolimus ensured that patients achieved their target levels. Further studies will be needed to elucidate the efficacy of top-down therapy with tacrolimus in patients with UC. Physicians must know how to use calcineurin inhibitors to obtain maximum efficacy.

AB - Background: Intravenous cyclosporine A (CsA) is an effective treatment for patients with severe, steroid-refractory ulcerative colitis (UC). Like the response to CsA, clinical trials have shown that two-thirds of patients with refractory UC respond to tacrolimus therapy. However, it is unclear how/when this agent should be used for patients with active UC. Methods: We reviewed the results of previous studies regarding calcineurin inhibitors in UC patients. We examined the best way to use tacrolimus to obtain maximum efficacy by comparing the results from clinical trials with those from a recent survey in Japan. Results: Calcineurin inhibitors are useful to induce remission in patients with refractory UC; however, the long-term prognosis has not been shown to be improved by CsA. Early intervention with CsA/tacrolimus may improve the long-term prognosis of UC patients just as infliximab does for Crohn's disease patients. Recent studies have indicated that a fasting state and administration of a higher dosage of tacrolimus at the beginning of therapy are critical in ensuring that the target trough concentration of the agent is reached. Conclusions: The use of higher initial doses of tacrolimus ensured that patients achieved their target levels. Further studies will be needed to elucidate the efficacy of top-down therapy with tacrolimus in patients with UC. Physicians must know how to use calcineurin inhibitors to obtain maximum efficacy.

KW - Cyclosporine A

KW - Infliximab

KW - Refractory ulcerative colitis

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=79954449661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954449661&partnerID=8YFLogxK

U2 - 10.1007/s00535-010-0352-z

DO - 10.1007/s00535-010-0352-z

M3 - Article

C2 - 21132334

AN - SCOPUS:79954449661

VL - 46

SP - 129

EP - 137

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 2

ER -